KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Total Non-Current Liabilities (2017 - 2025)

Moderna (MRNA) has disclosed Total Non-Current Liabilities for 9 consecutive years, with $2.5 billion as the latest value for Q3 2025.

  • On a quarterly basis, Total Non-Current Liabilities changed N/A to $2.5 billion in Q3 2025 year-over-year; TTM through Sep 2025 was $2.5 billion, a N/A change, with the full-year FY2024 number at $3.0 billion, down 31.09% from a year prior.
  • Total Non-Current Liabilities was $2.5 billion for Q3 2025 at Moderna, up from $2.4 billion in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $10.4 billion in Q4 2021 to a low of -$17.1 billion in Q2 2023.
  • A 5-year average of $1.2 billion and a median of $3.3 billion in 2024 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: surged 1981.85% in 2021, then tumbled 36.83% in 2022.
  • Moderna's Total Non-Current Liabilities stood at $10.4 billion in 2021, then crashed by 36.83% to $6.6 billion in 2022, then tumbled by 34.61% to $4.3 billion in 2023, then tumbled by 31.09% to $3.0 billion in 2024, then dropped by 15.13% to $2.5 billion in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Total Non-Current Liabilities are $2.5 billion (Q3 2025), $2.4 billion (Q1 2025), and $3.0 billion (Q4 2024).